You’ve seen the headlines: “Drug prices are skyrocketing.” “Congress rips Big Pharma over drug price hikes.” “Rising drug prices spark outrage.”

But the data tells a different story. Spending for prescription drugs overall has been pretty much flat, according to government and private industry sources, which found that U.S. consumer drug price increases are the lowest in decades.

That doesn’t mean that manufacturers haven’t been boosting the prices they set for their medications — they have. And sometimes by a lot.

Between 2002 and 2013, the average list price for insulin nearly tripled, according to a 2018 study in the journal Diabetes Care. The same study found that the average U.S. list price for the four insulin categories increased by 15 to 17 percent per year between 2012 and 2016.

Advertise with us

And although generic drug prices fell between 2008 and 2016, branded prescription drugs nearly tripled to an average $307.86 from $106.67 based on pharmacy benefit manager Express Scripts’ branded price index.

“Gross costs have been going up astronomically,” said Chronis Manolis, chief pharmacy officer at UPMC Health Plan, an arm of the Pittsburgh health care giant. “But like them or not, rebates are an integral part of the equation.”

Headline-grabbing stories about consumer drug prices can miss the discounts that manufacturers extend to insurers and many consumers, in part because those vary by plan. Here’s a peek under the hood.

Pharmacy benefit managers are the unseen middlemen in the prescription drug sales chain — negotiating manufacturer rebates, coordinating member services and managing benefit plans for employers, unions and other groups. Drugmakers pay rebates to these middlemen in exchange for spots on an employer’s formulary, the list of preferred drugs in a particular plan.

Getting on a formulary enhances sales, so raising list prices gives drug manufacturers negotiating leverage with PBMs because of the size of the rebates. Plus those high list prices and big rebates generate revenue for plan sponsors — and for pharmacy benefit manager services — encouraging list prices to float still higher.

Advertise with us

The bottom line is most people don’t see list prices, and fewer still pay the advertised price, which is rather like hotel rack rates rather than the actual price.

Some do pay sticker prices, of course. Those include: people without insurance; people with high-deductible health plans; Medicare recipients who reach their drug plan limit — the so-called doughnut hole, which was $3,750 in 2018; and contractors that administer benefits for people on Medicaid.

And the pain that causes can’t be ignored.

Most people with insurance pay discounted rates for their prescriptions.

So, while drugmakers jack up list prices — sometimes aggressively in the case of insulin — most consumers have been enjoying price increases that trail the cost of living.

Advertise with us

National health expenditures Based on 34.2 million member claims, Express Scripts’ employer plans reported overall prescription drug price increases of just 0.4 percent in 2018, the smallest increase in 25 years. The Centers for Medicare and Medicaid Services reported the same rate of prescription drug price increases for 2017. EXPRESS SCRIPTS EMPLOYER-SPONSORED PLANS*

*Methodology changed in 2015 to reflect impact of rebates. RETAIL PRESCRIPTION DRUG SPENDING

EXPRESS SCRIPTS SPECIALTY DRUG TREND

Note: Drug spending trends are based on prescription drug costs plus number of prescriptions filled. Source: Center for Medicare and Medicaid Services, Office of the Actuary, Express Scripts | Ed Yozwick/Post-Gazette

Studying the issue

Advertise with us

Three recent studies sounded the drug price alarm.

A Blue Cross Blue Shield Association study in November found that total prescription drug spending shot up 10 percent annually between 2010 and 2017. The Chicago-based trade association represents more than 40 million commercially insured members.

Another study by the University of Pittsburgh and UPMC Center for High-Value Health Care came to similar conclusions. Oral and injectable brand-name drugs jumped 9.2 percent and 15.1 percent, respectively, between 2008 and 2016, largely driven by drugs that had been on the market for a while, according to the study issued in January.

The Pitt-UPMC study also included an alarming example: The price of Sanofi’s Lantus brand insulin rose 49 percent since 2014, despite the drug being on the market for a decade.

But Sanofi’s average list drug prices overall rose just 4.6 percent in 2018 for its entire portfolio of drugs while its average net prices fell 8 percent.

Advertise with us

The discounting at Sanofi was even deeper in 2017: a 1.6 percent increase in the average list price for drugs versus an 8.4 percent decrease in net price, according to Adam Fein, CEO of Pembroke Consulting Group Inc., a Philadelphia-based industry consultant.

Other drugmakers are reporting higher discounts in 2019 while sticker prices head skyward.

Novartis AG said in January that its net prescription prices slipped last year and would continue downward this year in the low single-digit range, said chief executive Vas Narasimhan.

The issue in the Blue Cross and Pitt studies was the focus on manufacturer sticker prices for pharmaceuticals rather than the retail prices that most consumers pay.

Here’s where government studies may come into play. The federal Centers for Medicare and Medicaid Services’ Office of the Actuary annually collects information about U.S. health care spending, which includes prescription drug expenditures.

Advertise with us

Prescription drug spending — comprising 10 cents of every health care dollar spent — slowed in 2017, increasing just 0.4 percent to $333.4 billion, according to government data.

The 2017 growth rate follows a 2.3 percent rise in 2016, which was slower than the 8.9 percent in 2015 and much slower than in 2014, when drug spending rose 12.4 percent, according to CMS.

The last boom years in drug price increases were 2014 and 2015 — spikes attributed to expanded Medicaid benefits and higher costs for some drugs. In particular, costly new medications used to treat hepatitis C sent prices soaring. The drugs have been called a cure for what had been an incurable disease.

Specialty drugs up

Slowing drug price increases, according to the Centers for Medicare and Medicaid Services, can be attributed to slower growth in the number of prescriptions filled; continued shifts to lower-cost generic drugs; slower growth in the volume of some high-cost drugs prescribed; falling generic drug prices; and lower price increases for existing brand-name drugs.

Advertise with us

The same can’t be said for specialty drugs, which are costly by definition — prices for some products exceed $100,000 annually — while often requiring special handling and administration procedures.

Specialty drugs also drove global growth in pharmacy expenditures in 2018, according to Danbury, Conn.-based IQVIA Inc., which tracks issues related to prescription drugs.

But specialty growth has been the exception.

For Express Scripts commercial plan sponsor clients in 2018, specialty drug spending rose 9.4 percent, while spending on traditional drugs fell by 5.8 percent, Pembroke’s Mr. Fein said, with much of the specialty drug growth attributable to an increasing number of people using them.

“You don’t have to be a rocket surgeon to detect the downward trend since 2014,” he wrote in a February blog post.

Advertise with us

Increases in out-of-pocket spending by consumers for prescriptions also slowed in 2017 — with a 2.6 percent hike for the year lower than the 4.4 percent gain seen in 2016, CMS found. Of course, any increase may be hard to cope with at a time when wages have been largely stagnant.

Out-of-pocket health care spending — which includes such things as copayments, deductibles, and spending not covered by insurance — represents about 10 cents of every health care dollar, according to CMS.

Don’t trust government figures? Here’s a deeper dive into the private sector data.

The U.S. drug spending increase of 0.4 percent in 2018 was the lowest in 25 years, according to pharmacy benefit manager Express Scripts.

Drug spending for people with Medicare dipped 0.3 percent for the year.

Advertise with us

Half of pharmacy benefit plans, like the ones offered by employers as part of a health insurance package, decreased drug spending in 2018. That’s an increase from the 44 percent that saw decreased spending in 2017.

The average $11.55 price paid per 30-day prescription by Express Scripts clients in 2018 was just 6 cents higher than was paid in 2017, according to the company.

The list price strategy

Which prompts the question: Why have drug manufacturers been jacking up list prices in recent years? Here’s how pharmacy consultant Tom Cordeiro, president of Integrity Pharmaceutical Advisors LLC, of North Charleston, S.C., explained it.

Higher sticker prices are needed to offset bigger discounts given to pharmacy benefit managers, which administer prescription plans for more than 266 million Americans.

Advertise with us

The discounts help buy favorable placement for drugmakers’ products on drug formularies, which are the tiered lists of medicines that employees with prescription drug benefits follow.

There’s another reason for the list price spikes: Mr. Cordeiro said manufacturers raise prices on branded drugs that are nearing the end of patent protection to try to squeeze out a few more dollars of profit before low-cost generics shrink branded sales.

The practice has been going on for years, said the pharmacist who tells clients, including 450 California school districts, that his company can save them 10 to 20 percent on their total drug spending through a variety of strategies.

“Companies have become savvy in how they can improve their profitability,” Mr. Cordeiro said.

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699.